Your session is about to expire
← Back to Search
Implant
NT-501 for Macular Telangiectasia
Phase 3
Waitlist Available
Led By Emily Chew, MD
Research Sponsored by Neurotech Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 24 months.
Awards & highlights
Study Summary
This trial will test whether NT-501 implants are effective and safe for people with macular telangiectasia type 2.
Eligible Conditions
- Macular Telangiectasia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through 24 months.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 24 months.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of Change in Ellipsoid Zone (EZ) Area Loss
Secondary outcome measures
Mean Change in Aggregate Sensitivity of Microperimetry
Mean Change in Reading Speed
National Eye Institute-Visual Function Questionnaire (NEI-VFQ)
Side effects data
From 2019 Phase 2 trial • 22 Patients • NCT015306595%
Reversible Cardiac Vasospasm
5%
Secondary Surgical Intervention (excluding Posterior Capsulotomy)
5%
Pelvic fracture
5%
Pregnancy
5%
Total Eye Disorders
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sham Surgery
Prior to Randomization
NT-501 Implant
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NT-501Experimental Treatment1 Intervention
Group II: ShamPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NT-501
2017
Completed Phase 3
~390
Find a Location
Who is running the clinical trial?
Neurotech PharmaceuticalsLead Sponsor
10 Previous Clinical Trials
531 Total Patients Enrolled
1 Trials studying Macular Telangiectasia
64 Patients Enrolled for Macular Telangiectasia
Emily Chew, MDPrincipal InvestigatorNational Eye Institute (NEI)
3 Previous Clinical Trials
1,651 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger